VBS
0.44
66%
ERA
0.002
-33.3%
CBL
0.074
60.9%
LIB
0.002
-33.3%
BLZ
0.003
50%
CRN
0.265
-28.4%
RDS
0.003
50%
MRQ
0.004
-20%
SFG
0.003
50%
LML
0.009
-18.2%
C7A
0.004
33.3%
WTM
0.58
-17.1%
D3E
0.415
27.7%
BLU
0.005
-16.7%
PKO
0.005
25%
EUR
0.195
-15.2%
RNX
0.005
25%
AX8
0.006
-14.3%
ZNO
0.095
25%
VAR
0.006
-14.3%
CMO
0.022
22.2%
VRC
0.006
-14.3%
BMG
0.017
21.4%
PAB
0.037
-14%
GRL
0.017
21.4%
BMH
0.007
-12.5%
AKN
0.006
20%
FRX
0.014
-12.5%
AVE
0.006
20%
NGX
0.14
-12.5%
OVT
0.006
20%
OLY
0.063
-12.5%
FLG
0.185
19.4%
CC5
0.029
-12.1%
CVV
0.25
19%
TEK
0.115
-11.5%
MYG
2.35
18.1%
CMG
0.155
-11.4%
CZN
0.17
17.2%
ALM
0.008
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Chimeric Therapeutics (ASX:CHM): Reports first patient enrolled in chm clinical trial

Chimeric Therapeutics (ASX:CHM) has reported that the first participant has been enrolled in the Phase 1/2 multi-center clinical trial for CHM CDH17 cell therapy.

🩺 This therapy targets advanced gastrointestinal cancers like colorectal cancer, gastric cancer, and neuroendocrine tumors.
🏆 The trial aims to find the recommended dose and assess safety and effectiveness.

ASX announcement: https://announcements.asx.com.au/asxpdf/20240722/pdf/065szt55mn24fq.pdf